Cedric Moreau
Partner @ Sofinnova Partners
Paris, France
Cedric Moreau is a Series C investor at Sofinnova Partners in Paris focused on Medical and Health Care. Cedric Moreau is based out of Paris, Ile-de-France, and is the Partner of Sofinnova Partners and also works as the Board Director of Neurent Medical. Cedric previously worked at ODDO BHF as a Managing Director and Head of Healthcare in Corporate Finance. Cedric Moreau attended Pantheon-Sorbonne University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Cedric Moreau invests in
Stages Cedric Moreau invests in
Countries Cedric Moreau invests in
Investment Focus
Industry
- Medical 4 (44%)
- Health Care 4 (44%)
- Biotechnology 3 (33%)
- Medical Device 2 (22%)
- Genetics 1 (11%)
Stage
- Series C 2 (22%)
- Post-IPO Equity 2 (22%)
- Post-IPO Debt 1 (11%)
- Private Equity 1 (11%)
Country
- France 2 (22%)
- Ireland 2 (22%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neurent Medical
|
Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $74.5M / Series C / Feb 11, 2026 | |
Mainstay Medical
|
Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $125M / Private Equity / Feb 26, 2024 | |
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $5.4M / Post-IPO Equity / Feb 08, 2024 | |
Amolyt Pharma
|
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M / Series C / Jan 06, 2023 | |
|
Mainstay Medical
|
Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $108M / Private Equity / Feb 16, 2021 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $25M / Post-IPO Equity / Oct 22, 2020 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $16.5M / Post-IPO Debt / Dec 20, 2019 | |
|
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $8.8M / Post-IPO Equity / Feb 25, 2019 | |
|
Mainstay Medical
|
Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $32.9M / Post-IPO Equity / Feb 15, 2018 |
Co-Investors
About Sofinnova Partners
Sofinnova Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Cedric Moreau
Partner
|
|||
Alex Leech
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cedric Moreau invest in?
Cedric Moreau invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C and Post-IPO Equity stage. Most of the 9 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cedric Moreau last invest?
The most recent investment recorded for Cedric Moreau closed in Feb 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
